
    
      Phase 3b, randomized, multicenter, multinational, open-label, two-arm, active control,
      parallel study to determine safety, efficacy, and noninferiority of basal analog insulin
      lispro protamine suspension (ILPS, also referred to as NPL [neutral protamine Hagedorn]),
      injected two times a day, compared with basal analog insulin detemir, injected two times a
      day, as measured by change in hemoglobin A1c (HbA1c) from baseline (Visit 2) to 32 weeks in
      adult patients with type 1 diabetes when used in combination with bolus insulin lispro,
      injected three times a day.
    
  